Finesand - most of medicine is given to many patients with different doses .
IMO , the most important here is that we don’t see more side effects with higher dose .
I believe about 56% of patients did very well on P2 extension study .
This was a time when tests for CCR5 were not very accurate and dose was 350 mg .
Now tests are much better so patients selection is much better .
Also we know about different density of CCR5 , and dose of medicine is adjusted to 525 mg ,
I will expect big improvement in patients response ,
But of course mono study will prove one or another way .
Again the most important is that patients tolerating higher dose .
Not one serious side effect was reported by a company so far.